

Electronic Acknowledgement Receipt

EFS ID:	2305902
Application Number:	10577834
International Application Number:	
Confirmation Number:	6222
Title of Invention:	Muscarinic acetylcholine receptor antagonists
First Named Inventor/Applicant Name:	Zehong Wan
Customer Number:	20462
Filer:	Dara L. Dinner/Christina Boyer
Filer Authorized By:	Dara L. Dinner
Attorney Docket Number:	PU60574
Receipt Date:	11-OCT-2007
Filing Date:	01-MAY-2006
Time Stamp:	10:49:04
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	IDS.pdf	55298	no	1
			14446c114a5a79e12bf029513b0540115a8f09540		

Warnings:

Information:					
2	Information Disclosure Statement (IDS) Filed	1449.pdf	165245 909c2b63797624b8b95b7b716ab79c1d01e2	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	wo8705213.pdf	654832 4346e9242465a5e5565cb77ee191060328c0b1e	no	21
Warnings:					
Information:					
4	Foreign Reference	gb2242134.pdf	1891363 00632352f985dcb6971cd6215912a07a5713bc9	no	59
Warnings:					
Information:					
5	Foreign Reference	gb2178965.pdf	733161 f5e221c6d6998dc58f7b0edab671e42542e475	no	13
Warnings:					
Information:					
6	Foreign Reference	gb2129691.pdf	461307 9416a487249a05e7661ed87c3439937d82ca0d	no	7
Warnings:					
Information:					
7	NPL Documents	Brown_History_Basic_Properties.pdf	226196 903ecab47675109ca81dc309ed8576a15cd21	no	3
Warnings:					
Information:					
8	NPL Documents	Caulfield_Pharmac_Ther_1993.pdf	5296433 65a3eb401e841060233cb2b545a201046897c23a2	no	61
Warnings:					
Information:					
9	NPL Documents	Costello_Amer_J_Physio_1999.pdf	4007893 6b30da32b7e5de193a16f041a05e03aab05f0	no	6
Warnings:					
Information:					

10	NPL Documents	Fryer_Jacoby_Am_J_Respir_Crit_Care_Med.pdf	6444167 1571b2d7c83d6a9d9b120a489c3716914e211	no	7
Warnings:					
Information:					
11	NPL Documents	Fryer_et_al_Life_Sci_1999.pdf	460449 90a561905c0e8694833e03a5d7072ebMe20cad	no	7
Warnings:					
Information:					
12	NPL Documents	Hedge_et_al_life_sci_1999.pdf	576559 99955122a7c9f402a0a99a02ca25c1ba751fbd27db5	no	10
Warnings:					
Information:					
13	NPL Documents	lkeda_2002.pdf	940768 16ea31e68ff7144b3d69c665441fb3a3a0354e35	no	7
Warnings:					
Information:					
14	NPL Documents	Minette_et_al_J_appl_Phys_1989.pdf	586565 0173644039a879e5eb4dc3398a0783ba6b5915	no	5
Warnings:					
Information:					
15	NPL Documents	Oprins_et_al_Annals_NY_Acad_Sci_2000.pdf	74628 814a66e30eb3a305cd07082a0f654e4f0c489a49e	no	5
Warnings:					
Information:					
16	Foreign Reference	gb2169265.pdf	392150 6ddca74c3a727fa31255d99f55948c9d3ae1ba2	no	7
Warnings:					
Information:					
17	Foreign Reference	gb2064336.pdf	295429 6caea29c21973e67529093129ba7469f422ee5c19	no	5
Warnings:					
Information:					
18	Foreign Reference	EP0069715.pdf	567082 56bca38745d77a4db423b2f1e1e21e014c0b125	no	16
Warnings:					
Information:					

19	NPL Documents	Pauwels_et_al_Am_j_Respir _Crit_Care_Med_2001.pdf	262392 f5cd64325393cfbc7031458b4d0300 031b1bb2	no	21
Warnings:					
Information:					
20	NPL Documents	RanAbstract.pdf	17051 e6e3a0d2c2b52e4a32b341195eb48e4a7 a354a03b9	no	2
Warnings:					
Information:					
21	NPL Documents	SarauMolPharm1999.pdf	234511 80c151a8410903319ec5c01630315c5 c0b03b9	no	7
Warnings:					
Information:					
22	NPL Documents	VanRossumClear.pdf	831266 e2081d531ad379230a3f5955044cc76 e201d50	no	32
Warnings:					
Information:					
23	NPL Documents	WuAbstract.pdf	10985 e65e20bc7e0dc14a75fe4e7195d34d1 19857aa4	no	1
Warnings:					
Information:					
24	NPL Documents	zhang.pdf	1354664 a1f6ef37bc11d1d7ba0a3a30561a5d5856 90217c	no	9
Warnings:					
Information:					
25	NPL Documents	ZirkleJMedPharmChem.pdf	651696 439500357535d2778bc826d229cb3709 e195e203d	no	9
Warnings:					
Information:					
26	NPL Documents	ZirkleJMedPharmChempart1 .pdf	389022 27918e17762c2b44c0893d01194c078 ecb138f	no	11
Warnings:					
Information:					
27	NPL Documents	ZirkleJMedPharmChempart2 .pdf	283573 ff5550e508ba631379a5b9973819c3b5b 74662ab	no	7
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.